Alexion Australia is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. Alexion established operations in Sydney in 2008 to serve patients in the Australian region. We aim to work in partnership with stakeholders including healthcare providers, patient advocacy organisations, and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we aim to help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.

We are guided to help people with rare diseases and their families live their best lives.  We understand that the rare disease community face major obstacles that put them at a significant disadvantage, and their conditions can have a profound impact on patients, their families and society.

We believe it is our responsibility to change the lives of patients and their caregivers by developing and delivering transformative medicines.  We currently have approved treatments in Australia that help patients with Paroxysmal Nocturnal Haemoglobinuria, a typical Haemolytic Uraemic Syndrome, Hypophosphatasia, Lysosomal  Acid Lipase Deficiency*, Neuromyelitis Optica Spectrum Disorder*, and Plexiform Neurofibromas in NF1*.

We are proud supporters of the Children’s Tumour Foundation, recognising the vital support and services they provide to the NF community, and we are privileged to sponsor their 2023 Clinical Symposium.